Amendment to 4.75% Senior Convertible NotesConvertible Notes • June 18th, 2007 • Novavax Inc • Biological products, (no disgnostic substances)
This amendment agreement (this “Amendment”) dated June 15, 2007 to the 4.75% senior convertible notes issued pursuant to the Purchase Agreement (as defined below) (the “Notes”) is made by and between Novavax Inc., a Delaware corporation (the “Company”) and Smithfield Fiduciary LLC (the “Investor”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Notes.
FIFTH AMENDMENT TO CONVERTIBLE NOTESConvertible Notes • April 22nd, 2014 • Bohai Pharmaceuticals Group, Inc. • Pharmaceutical preparations • New York
This FIFTH AMENDMENT TO CONVERTIBLE NOTES (this “Amendment”) is made and entered into as of April 21, 2014 by and between Bohai Pharmaceuticals Group, Inc., a Nevada corporation (the “Company”), and Euro Pacific Capital, Inc. (the “Investor Representative”).
AMENDMENT TO CONVERTIBLE NOTESConvertible Notes • January 4th, 2011 • Quantum Fuel Systems Technologies Worldwide, Inc. • Motor vehicle parts & accessories
This Amendment to the Convertible Notes (as defined below) is made and entered into as of January 3, 2011 by Quantum Fuel Systems Technologies Worldwide, Inc., a Delaware corporation (the "Company"), and WB QT, LLC, a Delaware limited liability company (the "Purchaser"). The Company is indebted to the Purchaser under the following convertible promissory notes (the "Convertible Notes"):
AMENDMENT TO 8% CONVERTIBLE NOTESConvertible Notes • March 30th, 2017 • International Isotopes Inc • Industrial instruments for measurement, display, and control • New York
This Amendment to 8% Convertible Notes (this “Agreement”) is dated as of March 24, 2017 by and between Euro Pacific Capital Inc. (“Euro Pacific Capital”) and International Isotopes Inc. (the “Company”).
TERM SHEET FOR REDEMPTION OF CONVERTIBLE NOTESConvertible Notes • November 12th, 2008 • Kiwa Bio-Tech Products Group Corp • Grain mill products
This Term Sheet is entered into by and among Kiwa Bio-Tech Products Group Corporation (the “Company”) and AJW Offshore Ltd., AJW Qualified Partners LLC, AJW Partners LLC, and New Millennium Capital Partners II LLC (collectively the “NIR Group.”) as of September 25, 2008.
AMENDMENT TO CONVERTIBLE NOTESConvertible Notes • January 5th, 2012 • Bohai Pharmaceuticals Group, Inc. • Pharmaceutical preparations • New York
This AMENDMENT TO CONVERTIBLE NOTES (this “Amendment”) is made and entered into as of December 31, 2011 by and between Bohai Pharmaceuticals Group, Inc., a Nevada corporation (the “Company”), and Euro Pacific Capital, Inc. (the “Investor Representative”).
Oiltek, Inc.Convertible Notes • April 3rd, 2009 • Oiltek, Inc. • Oil & gas field machinery & equipment
Reference is made to the Convertible Notes (the “Notes”) dated various dates between Avalon Oil & Gas (the “Payee”) and Oiltek, Inc. (the “Payor”) in the aggregate amount of $77,400. This will confirm our agreement to amend the terms and conditions of the Notes as follows:
CONVERTIBLE NOTESConvertible Notes • March 14th, 2017
$485,000 and detailed in Appendix 3B (lodged with ASX on 28 February 2017) and Appendix 3Y (lodged with ASX on 1 March 2017). The Company seeks to clarify that the Hicks Agreement is in actual fact a converting loan agreement with a related party and therefore the convertible loan is treated as a loan and not a security until the loan is converted. In regards to the Hicks Agreement, shareholder approval under ASX Listing Rule 10.11 is required to allow convertibility. The Company has also entered into a number of similar convertible note agreements with other third party unrelated investors. These do not require shareholder approval.
Amendment to Convertible NotesConvertible Notes • May 8th, 2019 • Aethlon Medical Inc • Laboratory analytical instruments • New York
This Amendment to Convertible Notes (this “Agreement”), effective as of May 6, 2019 (the “Effective Date”), is made by and among Aethlon Medical, Inc., a Nevada corporation (the “Company”), and the undersigned holders (collectively, the “Note Holders”) of outstanding Convertible Notes issued by the Company on November 6, 2014 and December 30, 2016, as amended to date, as detailed on Exhibit A attached hereto (the “Notes”); and
AMENDMENT TO CONVERTIBLE NOTESConvertible Notes • January 5th, 2018 • Cel Sci Corp • Biological products, (no disgnostic substances)
AMENDMENT TO SECURED SUBORDINATED CONVERTIBLE NOTESConvertible Notes • May 28th, 2024 • Venus Concept Inc. • Surgical & medical instruments & apparatus
This Amendment to Secured Subordinated Convertible Notes (this “Amendment”), dated as of May 24, 2024 (the “Effective Date”), is entered into by and among Venus Concept Inc., a Delaware corporation (the “Company”), Venus Concept USA Inc. (“Venus USA”), Venus Concept Canada Corp. (“Venus Canada”), Venus Concept Ltd. (“Venus Israel” and together with Venus USA and Venus Canada, the “Guarantors”), Madryn Health Partners, LP, a Delaware limited partnership (“Madryn”), Madryn Health Partners (Cayman Master), LP, a Cayman Islands limited partnership (“Madryn Cayman,” and together with Madryn, each in their capacity as Holder under the Notes, the “Investors”), and Madryn Health Partners, LP, in its capacity as Collateral Agent under the Guaranty and Security Agreement (the “Collateral Agent”, and together with the Company, the Guarantors and the Investors, the “Parties”).
FOURTH AMENDMENT TO CONVERTIBLE NOTESConvertible Notes • December 6th, 2012 • Bohai Pharmaceuticals Group, Inc. • Pharmaceutical preparations • New York
This FOURTH AMENDMENT TO CONVERTIBLE NOTES (this “Amendment”) is made and entered into as of December 6, 2012 by and between Bohai Pharmaceuticals Group, Inc., a Nevada corporation (the “Company”), and Euro Pacific Capital, Inc. (the “Investor Representative”).
AMENDMENT AND WAIVER OF 6% SERIES B CONVERTIBLE NOTESConvertible Notes • December 6th, 2007 • nCoat, Inc. • Coating, engraving & allied services
TERM SHEET FOR REDEMPTION OF CONVERTIBLE NOTESConvertible Notes • November 12th, 2008 • Kiwa Bio-Tech Products Group Corp • Grain mill products
This Term Sheet is entered into by and among Kiwa Bio-Tech Products Group Corporation (the “Company”) and FirsTrust Group, Inc. (the “FirsTrust Group.”) as of October 7, 2008.
SECOND AMENDMENT TO CONVERTIBLE NOTESConvertible Notes • May 15th, 2012 • Bohai Pharmaceuticals Group, Inc. • Pharmaceutical preparations • New York
This SECOND AMENDMENT TO CONVERTIBLE NOTES (this “Amendment”) is made and entered into as of May 15, 2012 by and between Bohai Pharmaceuticals Group, Inc., a Nevada corporation (the “Company”), and Euro Pacific Capital, Inc. (the “Investor Representative”).
OMNIBUS AMENDMENT TO CONVERTIBLE NOTESConvertible Notes • January 12th, 2018 • CLS Holdings USA, Inc. • Retail-miscellaneous retail
THIS OMNIBUS AMENDMENT TO CONVERTIBLE NOTES (the “Agreement”) is made this 10th day of January, 2018, effective as of December 1, 2017, by and among CLS Holdings USA, Inc., a Nevada corporation (“CLSH”), Jeffrey I. Binder (“Binder”) and Newcan Investment Partners, LLC (“Newcan”) with respect to the convertible promissory notes set forth on Exhibit A hereto (collectively, the “Notes”) issued by CLSH to either Binder or Newcan.
ARTICLE IConvertible Notes • October 13th, 1998 • Interiors Inc • Lumber & wood products (no furniture) • New York
THIRD AMENDMENT TO CONVERTIBLE NOTESConvertible Notes • June 28th, 2012 • Bohai Pharmaceuticals Group, Inc. • Pharmaceutical preparations • New York
This THIRD AMENDMENT TO CONVERTIBLE NOTES (this “Amendment”) is made and entered into as of June 27, 2012 by and between Bohai Pharmaceuticals Group, Inc., a Nevada corporation (the “Company”), and Euro Pacific Capital, Inc. (the “Investor Representative”).
